The Radiopharmaceutical Blueprint: Navigating the Ecosystem from Isotope to Infusion
Radiopharma raised more capital between 2023 and 2025 than in its entire prior history, and the infrastructure underneath it did not keep pace. This report maps the full ecosystem - isotopes, manufacturing, logistics, clinical execution and people - and argues the binding constraint has moved from science to execution.
What this report answers
- Which strategic model is a radiopharma developer actually running, and does it survive the next five years?
- Why were the recent multi-billion-dollar acquisitions priced well above their pipelines?
- Who can genuinely manufacture an alpha-emitting therapeutic to GMP, and who only claims to?
- Which CROs, imaging core labs and dosimetry providers have real radioligand therapy experience?
- What actually stops a radioligand trial from activating its clinical sites on time?
- Which roles are the real rate-limiter on growth, and where is the shortage most acute?
5-to-1
the ratio by which the report estimates demand for its multidisciplinary radiopharma leadership profile exceeds available supply, sharpest where alpha-emitter experience is required.
five to ten
new radiochemistry PhDs the report cites as being granted annually in the United States - the figure it uses to argue the educational pipeline cannot close the gap on its own.
What the analysis establishes
The gold rush paradox
The report sets out the structural conflict it treats as the organising fact of the sector: a historic wave of capital meeting an infrastructure that was never built to absorb it. It defines a scarcity triad across isotopes, manufacturing and people, and explains why each leg constrains the others rather than acting independently.
Five strategic archetypes among developers
Rather than ranking companies by pipeline, the analysis sorts developers into distinct operating models - from capital-heavy acquirers to vertically integrated challengers and niche platform plays - and works through what each archetype must control to survive. It names the companies sitting in each, and what their isotope choice reveals about their supply-chain philosophy.
The manufacturing gauntlet
A profile of the foundational layer: who produces the therapeutic isotopes, by which production route, and where the fragility sits. It then maps the GMP CDMO market as it bifurcates into pure-play and hybrid models, and lists the enabling technology suppliers - hot cells, synthesisers, shielding - that every facility depends on.
Clinical execution and the site activation problem
A working directory of the specialist clinical layer: full-service and niche CROs, imaging core labs, dosimetry services and site support providers, each with its positioning and the specific radioligand services it offers. The chapter establishes why generalist oncology partners fail here and how thin the genuinely experienced pool is.
Logistics under the decay clock
The report treats the product as a decaying asset and follows it through the supply chain: specialist Class 7 couriers, national radiopharmacy networks doing final dose preparation, and the reverse logistics of radioactive waste. It sets out why last-mile control has become a strategic asset rather than a procurement line.
The human capital crisis
The chapter defines the multidisciplinary leadership profile the sector now competes for, quantifies the gap between demand and supply, and identifies the company types where hiring pressure is most acute. It also explains how team scarcity has been showing up inside acquisition premiums.
How it was built
Synthesised from publicly available sources - company disclosures, transaction announcements, regulatory filings, trial registries and provider material - and assembled into an operational map rather than a market forecast. Coverage is structured as directories with stated positioning for each organisation, so a reader can check the classification against their own knowledge. Forward-looking chapters are labelled as predictions and are ProGen Search's own view, current as of Q3 2025.
Written for radiopharma executives, investors and board members making build-or-buy, partner-selection and hiring decisions, and for service providers positioning against the ecosystem as it now stands.
Contents
- An Industry at an Inflection Point: The Gold Rush Paradox
- The Innovators: Mapping the RLT Developer Landscape
- The Manufacturing Gauntlet: From Isotope to Aseptic Vial
- The Clinical Execution Engine: A Directory of Specialist Partners
- The 'Just-in-Time' Logistics Web: Profiling the Key Networks
- The Interconnected Ecosystem: Mapping the Network of Partnerships
- The Human Capital Crisis: Execution Under Scarcity
- Horizon Scan: Future Predictions for the RLT Ecosystem
- The 5-Year Roadmap: A Call to Action for the RLT Ecosystem
- Appendix A: Comprehensive Index of Radiopharmaceutical Ecosystem Players
Organisations covered
Novartis, Bristol Myers Squibb, Eli Lilly and Company, AstraZeneca, Bayer, Telix Pharmaceuticals, Lantheus Holdings, Curium Pharma, ITM Isotope Technologies Munich, Orano Med, NorthStar Medical Radioisotopes, BWXT Medical, SHINE Technologies, Eckert & Ziegler, Nucleus RadioPharma, AtomVie Global Radiopharma, SpectronRx, PharmaLogic, Cardinal Health, SOFIE Biosciences, Jubilant Radiopharma, Medpace, PSI CRO, Perceptive, Voximetry
The full 33-page briefing is free. Tell us where to send it and it downloads immediately.
The State of Radiopharmaceuticals 2026
This blueprint maps the ecosystem as it stood in Q3 2025. The flagship 2026 report rebuilds the picture from primary data, with named capacity, current programme economics and where the constraints have moved since.
See the full report →